Clinical trial
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV…
NCT00002227 · Dupont Merck, Industry · Completed
Key facts
| NCT number | NCT00002227 |
|---|---|
| Title | A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs |
| Official title | A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients |
| Lead sponsor | Dupont Merck, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Efavirenz, Lamivudine, Stavudine |
| Enrollment | 60 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: